Physician profile
Jack M Mann
NPI 1376542217
$736,027.59
in general payments reported to CMS, 2019-2025
34 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181K · 2020: $151K · 2021: $121K · 2022: $121K · 2023: $44K · 2024: $51K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Consulting Fee: $9,646 · Food and Beverage: $8,869 · Travel and Lodging: $5,736 · Education: $262 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,970.00 |
| Consulting Fee | $9,646.00 |
| Food and Beverage | $8,869.22 |
| Travel and Lodging | $5,736.30 |
| Education | $262.13 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $377,599.41 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $142,348.77 | 2019-2025 | Nucala, Trelegy Ellipta |
| Mallinckrodt Enterprises LLC | $74,812.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68,895.55 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $38,004.38 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $17,882.23 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $11,013.17 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $874.50 | 2019-2025 | Opsumit |
| Philips North America LLC | $512.87 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Grifols USA, LLC | $505.88 | 2019-2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $477.46 | 2022-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $347.52 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.44 | 2019-2025 | |
| Advanced Respiratory, INC | $300.71 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $286.46 | 2019-2025 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $274.60 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $258.26 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $254.49 | 2020-2025 | Glassia, Aralast |
| Ani Pharmaceuticals, INC. | $196.63 | 2022-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $171.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $127.55 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $87.42 | 2019-2020 | |
| United Therapeutics Corporation | $86.99 | 2019-2022 | |
| Amgen INC. | $84.82 | 2022-2025 | Tezspire |
| Inspire Medical Systems, INC. | $52.48 | 2025 | Inspire |
| Shire North American Group INC | $49.80 | 2019 | |
| Viatris Specialty LLC | $47.56 | 2025 | Yupelri |
| Gilead Sciences, INC. | $40.40 | 2019-2025 | Veklury |
| Teva Pharmaceuticals USA, INC. | $29.37 | 2019-2022 | |
| Phadia US INC. | $20.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.38 | 2023 | Cycloset |
| Pfizer INC. | $14.43 | 2024 | |
| Circassia INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.